x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:11:34

RBC Global Healthcare Conference: With a phase 3 for...

BiotechTV - News ·

2025/05/21

CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic diseases, especially pulmonary disease. He sets up the phase 3 for Efzofitimod in pulmonary sarcoidosis, and also pending data in systemic sclerosis.

en-us

00:15:15

RBC Global Healthcare Conference: Ocular...

BiotechTV - News ·

2025/05/21

He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including the rationale for recent changes to them. Plus an update on the NPDR indication.

en-us

00:09:15

RBC Global Healthcare Conference: RBC's Brian...

BiotechTV - News ·

2025/05/21

He describes some of the discussions he is having at the conference, discusses the difference between how large companies he covers are handling volatility vs smaller ones, and offers his take on the prospects for M&A.

en-us

00:17:04

RBC Global Healthcare Conference: Ahead of an...

BiotechTV - News ·

2025/05/21

He describes the science behind Cidara's Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu changes each season. Plus, a preview of next month's readout, and how FDA discussions around this have been.

en-us

00:09:34

Stevenage, UK based TessellateBio recently signed a...

BiotechTV - News ·

2025/05/20

CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with Boehring Ingelheim on, which seeks to interrupt some cancers' ability to harness telomeres to continuously replicate. The deal is potentially work in excess of €500 million. Plus addition programs, including one targeting SKP2.

en-us

00:14:21

Cambridge, UK based Maxion Therapeutics raised a $72M...

BiotechTV - News ·

2025/05/16

CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things like inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.

en-us

00:08:34

ASGCT 2025: HuidaGene presented preclinical and early...

BiotechTV - News ·

2025/05/16

CEO Alvin Luk and CTO TJ Cradick explain how the company's Cas12 and 13 programs are different than Cas9, and they discuss the DMD presentation and how this program differs from the current microdystrophin product that is on the market. Plus, RNA editing programs targeting neovascular age-related macular degeneration and MECP2 Duplication Syndrome (MDS), and a DNA program targeting ALS.

en-us

00:10:42

ASGCT 2025: Dyno Therapeutics CEO Eric Kelsic...

BiotechTV - News ·

2025/05/15

He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body. Plus, the company's new 'Frontiers Program' and a Genetic Agency Technology Conference coming up in November.

en-us

00:17:24

ASGCT 2025: Physicians and scientists raced to make a...

BiotechTV - News ·

2025/05/15

As published in NEJM today, UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant with CPS1 deficiently, and his thoughts on what the learnings of this case are for drug development.

en-us

00:09:53

ASGCT 2025: Coave Therapeutics presented a late...

BiotechTV - News ·

2025/05/15

CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered program. Plus, comments on the company's IV program for CNS conditions, and a recent €32 million series A.

en-us

00:11:31

Cambridge, UK based Alchemab Therapeutics last week...

BiotechTV - News ·

2025/05/15

CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand why, and discusses this week's deal and the company's prior one with Lilly as well.

en-us

00:07:12

ASGCT 2025: The Co-Founder of ProQR discusses the...

BiotechTV - News ·

2025/05/15

ProQR Co-Founder & CSO Gerard Platenburg describes the company's RNA editing platform and the journey he has seen this field go through over time. Plus, updates on programs for cholestatic diseases, Rhett Syndrome, and MASH.

en-us

00:10:06

ASGCT 2025: Capsida Biotherapeutics is using its...

BiotechTV - News ·

2025/05/14

CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A first program recently had its IND cleared.

en-us

00:09:27

ASGCT 2025: The co-founders of Circio describe the...

BiotechTV - News ·

2025/05/14

CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered circular RNA in humans over a decade ago. They discuss potential use cases, including using it for in-vivo CAR-T, something that has been talked about a lot at this year's conference.

en-us

00:12:30

Gene therapies expert TJ Cradick previews what to...

BiotechTV - News ·

2025/05/13

He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and gene therapies progresses.

en-us

00:17:00

Inductive Bio raised a $25M series A last week to...

BiotechTV - News ·

2025/05/13

Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized.

en-us

00:19:34

NewLimit raised a $130M series B round last week to...

BiotechTV - News ·

2025/05/12

Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.

en-us

00:19:03

Biotech investor Christoph Broja of EQT Life Sciences...

BiotechTV - News ·

2025/05/09

He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on the value of being local for uncovering opportunities, and the state of the capital markets.

en-us

00:13:18

With a phase 3 trial for its PRAME cell therapy...

BiotechTV - News ·

2025/05/09

CEO Harpreet Singh joins us from the company's office in Munich, Germany, where he describes the founding of the company and previews catalysts to watch for over the year ahead.

en-us

00:06:59

Mosaic Therapeutics, which uses advanced...

BiotechTV - News ·

2025/05/09

Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.

en-us

362 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter